# Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)

> **NCT03603288** · PHASE3 · TERMINATED · sponsor: **Santhera Pharmaceuticals** · enrollment: 161 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** idebenone 150 mg film-coated tablets

## Key facts

- **NCT ID:** NCT03603288
- **Lead sponsor:** Santhera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-04
- **Primary completion:** 2020-11-25
- **Final completion:** 2020-11-25
- **Target enrollment:** 161 (ACTUAL)
- **Why stopped:** Interim analysis concluded to futility of main study SIDEROS (SNT-III-012)
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603288, "Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03603288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*